5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details
臨床試験数 : 95 / 薬物数 : 119 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04658199 (ClinicalTrials.gov) | November 16, 2020 | 1/12/2020 | A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy | An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy | Progressive Supranuclear Palsy | Drug: UCB0107 (bepranemab) | UCB Biopharma SRL | NULL | Active, not recruiting | 40 Years | N/A | All | 19 | Phase 1 | Belgium;Germany;Spain;United Kingdom |
| 2 | NCT04185415 (ClinicalTrials.gov) | December 3, 2019 | 2/12/2019 | A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) | A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) | Progressive Supranuclear Palsy | Drug: bepranemab;Drug: Placebo | UCB Biopharma SRL | NULL | Completed | 40 Years | N/A | All | 25 | Phase 1 | Belgium;Germany;Spain;United Kingdom |